Call Us: 1.800.873.5297


Gynecologists Continue Using Power Morcellators Despite FDA Warning, The Wall Street Journal Reports

The Wall Street Journal reports that doctors nationwide are continuing to use a popular surgical tool, known as power morcellators, even after the United States Food and Drug Administration (FDA) warned that the device can spread undetected cancer. The Wall Street Journal notes that this demonstrates “the limits of the regulator’s reach into clinical practice.” In […]


Actos® MDL Update: $9B Jury Verdict Against Takeda & Eli Lilly in First Actos MDL Trial Reduced to $36.8M

Law360 reports that the jury verdict of $9 billion in punitive damages against Takeda and Eli Lilly over the type II diabetes drug, Actos®, in the first federal trial has been reduced to $36.8 million. In particular, Judge Doherty ruled that although the verdict was not unreasonable, the jury “should bow” to the Constitution’s due […]


American Cancer Society: Mixed Findings on Link between Talcum Powder & Ovarian Cancer

The American Cancer Society has weighed in on the suggestion that talcum powder may cause ovarian cancer. In particular, the American Cancer Society provides that “it has been suggested that talcum powder might cause cancer in the ovaries if the powder particles (applied to the genital area or on sanitary napkins, diaphragms, or condoms) were […]


FDA Remains Undecided Regarding the Potential Ban on Power Morcellators

The Democrat & Chronicle reports that the Food and Drug Administration (FDA) held hearings more than two months ago regarding the issue of whether to ban power morcellators. However, the FDA has yet to rule on the issue and affected families are outraged about the delay. FDA spokesperson Morgan Liscinsky provided, “The FDA is considering […]


Actos® Lawsuit Update: Jurors in Philadelphia Hear Evidence that Takeda Concealed Bladder Cancer Risks, Law 360 Reports

Law 360 reports that jurors in a Philadelphia state court case trial heard evidence from an expert witness who testified that Takeda worked to suppress information about the cancer risks associated with Actos®. Randall Tackett, an expert witness who testified on behalf of plaintiff Frances Wisniewski, testified that Takeda convinced one of its partners back […]


Ingredient in Colgate Total Toothpaste Linked to Cancer, Bloomberg Reports

Bloomberg reports that an active ingredient in Colgate Total toothpaste, Triclosan, is linked to cancer-cell growth and disrupted development in animals. Although many companies have stopped using this antibacterial chemical in their products, Colgate stands by its use of Triclosan citing the FDA’s approval of its product as an over-the-counter drug in 1997. However, Bloomberg […]


Hysterectomy Device May Spread Undetected Cancer, New Study Finds

The Wall Street Journal reports that a surgical device used to remove uterine fibroids and during hysterectomies may spread previously undetected cancerous tissue inside the body, according to a recent study published in the Journal of the American Medical Association (JAMA). The study, conducted by Columbia University doctors, found that 1 in 368 women who […]


Researchers Aim to Test Experimental Drugs to Alter Circadian Rhythms

Two neurology professors aim to begin testing drugs that could positively alter the body’s circadian rhythms (i.e., the body’s internal clock that control it’s biological workings from sleeping and eating to cardiovascular function). Studies have shown that disrupting the body’s internal clock, for example by working night shift, can increase an individual’s risk for developing […]


Infuse® Bone Graft Lawsuit Update: New Studies Reveal Increased Risk of Cancer and Male Infertility

During spinal surgeries, doctors traditionally used graft material taken from another part of the patient’s body and inserted it into the space between two vertebrae to promote bone growth, improve stability, and relieve back pain. In 2002, Medtronic began marketing the Infuse® Bone Graft as a better alternative to traditional bone removal and grafting. Rather […]


FDA Investigates Vytorin

Vytorin is a combination of simvastatin (Zocor) and ezetimibe (Zetia). Vytorin reduces the amount of cholesterol (a type of fat) absorbed by the body and block the production of cholesterol in the body. In August 2008, the U.S. Food and Drug Administration (FDA) issued an Early Communication describing a possible association between the use of […]

000-017   000-080   000-089   000-104   000-105   000-106   070-461   100-101   100-105  , 100-105  , 101   101-400   102-400   1V0-601   1Y0-201   1Z0-051   1Z0-060   1Z0-061   1Z0-144   1z0-434   1Z0-803   1Z0-804   1z0-808   200-101   200-120   200-125  , 200-125  , 200-310   200-355   210-060   210-065   210-260   220-801   220-802   220-901   220-902   2V0-620   2V0-621   2V0-621D   300-070   300-075   300-101   300-115   300-135   3002   300-206   300-208   300-209   300-320   350-001   350-018   350-029   350-030   350-050   350-060   350-080   352-001   400-051   400-101   400-201   500-260   640-692   640-911   640-916   642-732   642-999   700-501   70-177   70-178   70-243   70-246   70-270   70-346   70-347   70-410   70-411   70-412   70-413   70-417   70-461   70-462   70-463   70-480   70-483   70-486   70-487   70-488   70-532   70-533   70-534   70-980   74-678   810-403   9A0-385   9L0-012   9L0-066   ADM-201   AWS-SYSOPS   C_TFIN52_66   c2010-652   c2010-657   CAP   CAS-002   CCA-500   CISM   CISSP   CRISC   EX200   EX300   HP0-S42   ICBB   ICGB   ITILFND   JK0-022   JN0-102   JN0-360   LX0-103   LX0-104   M70-101   MB2-704   MB2-707   MB5-705   MB6-703   N10-006   NS0-157   NSE4   OG0-091   OG0-093   PEGACPBA71V1   PMP   PR000041   SSCP   SY0-401   VCP550  

Legal Disclaimer & Privacy Policy
This web site is designed for general information only. The information presented should not be construed as legal advice and does not form the basis for an attorney/client relationship.

The choice of a lawyer is an important decision and should not be based solely on advertisements.
This web site is not intended to be advertising, and Schlichter Bogard & Denton LLP does not desire to represent anyone desiring representation based upon viewing this web site in a jurisdiction where this web site fails to comply with all laws and ethical rules of that jurisdiction. Materials on this web site may only be reproduced in their entirety (without modification) for the individual reader's personal and/or educational use and must include this notice.

We will not disclose, sell, or rent any of your identifiable personal information to any third party, unless approved by you, or required by law.